CompletedNot Applicable

Tumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma

France11 participantsStarted 2024-11-01

Plain-language summary

The hypothesis for this study is that there is a dose-response relationship in patients treated with 177Lu-DOTATATE for meningiomas.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients treated for menigioma at nancy hospital * patients who performed 3 scintigraphics exams during there treatment Exclusion Criteria: * patients deprived of liberty * patient who refused to collect data retrospectively

What they're measuring

Diagnostic accuracy for progression free survival

Timeframe: Day 1

Trial details

NCT IDNCT06614205

SponsorCentral Hospital, Nancy, France

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-01-01

View on ClinicalTrials.gov More Meningioma of Brain trials